Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joel Linden
La Jolla Inst for Allergy & Immunolgy, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Adenosine Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The funded research studies the use of regadenoson for the treatment of sickle cell disease. Dr. Linden is an inventor on US patent application 8,178,509 “Method to treat sickle cell disease” owned by the University of Virginia and could receive royalty payments from Adenosine Therapeutics if Regadenoson is approved for treatment of sickle cell disease. Dr. Linden also has equity in Adenosine Therapeutics which has licensed the patent application from the University of Virgina.
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease
Project Narrative This project will use ultrasound to measure tissue vascular perfusion, and will analyze white blood cells from patients with sickle cell anemia. These procedures will provide us with measures of abnormalities in blood flow and inflammation that will be used to better understand the disease, and also to help evaluate the effectiveness of new therapeutic approaches.
Filed on January 14, 2016.
Tell us what you know about Joel Linden's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Joel Linden filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Joel Linden | Dana Farber Cancer Inst | Conflict of Interest | Adenosine Therapeutcis | >$600,000 |
| Joel Linden | La Jolla Inst for Allergy & Immunolgy | Conflict of Interest | Adenosine Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.